Breaking News Instant updates and real-time market news.

INO

Inovio

$6.27

0.92 (17.20%)

, RHHBY

Roche

$0.00

(0.00%)

13:07
10/02/18
10/02
13:07
10/02/18
13:07

Inovio spikes higher after positive data published

Shares of Inovio (INO) are spiking higher after the company announced the publication of results in a major cancer journal, from a study of MEDI0457. TREATED WITH MEDI0457: According to an earlier statement from Inovio, a paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response on treatment with a subsequent PD-1 checkpoint inhibitor. In the Inovio-sponsored study of 22 patients with head and neck squamous cell carcinoma, the company reported 91% showed T cell activity in the blood or tissue. MEDI0457 -- formerly called INO-3112 -- was in 2015 licensed to MedImmune, the global biologics research and development arm of AstraZeneca (AZN). These immune data, as well as the financial terms of the license agreement, have been previously reported by Inovio. STUDY SUPPORTS HPV AND ONCOLOGY PROGRAMS: Inovio CEO Dr. J. Joseph Kim said, "We are buoyed by the study as it lends support to all of our HPV and oncology programs. These data demonstrated that Inovio's technology based in MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. The study supports our belief that this approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated head and neck and other types of cancer to improve therapeutic outcomes. Inovio is collaborating with MedImmune as well as Genentech (RHHBY) and Regeneron (REGN) in efficacy trials coupling Inovio's DNA-based cancer immunotherapies with checkpoint inhibitors designed to increase response rates with data expected in 2019." ANALYST RAISES PRICE TARGET: Stifel analyst Stephen Willey resumed coverage of Inovio with a Buy rating and $8 price target, citing his favorable view of the clinical risk underlying the ongoing Phase 3 VGX-3100 development program in patients with HPV+ cervical HSIL. He sees the company's earlier-stage immuno-oncology development efforts and externally-funded infectious diseases programs as additional sources of longer-term upside. PRICE ACTION: Shares of Inovio Pharmaceuticals are up over 16% to $6.22 per share in afternoon trading.

INO

Inovio

$6.27

0.92 (17.20%)

RHHBY

Roche

$0.00

(0.00%)

AZN

AstraZeneca

$39.55

0.05 (0.13%)

REGN

Regeneron

$403.35

9.33 (2.37%)

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 20

    Oct

  • 28

    Oct

  • 28

    Apr

  • 13

    May

INO Inovio
$6.27

0.92 (17.20%)

09/26/18
PIPR
09/26/18
NO CHANGE
Target $12
PIPR
Overweight
Piper remains buyer of Inovio after management meetings
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Inovio Pharmaceuticals with a $12 price target following a day of investor meetings with management. The analyst looks to 2019 efficacy updates for MEDI0457 and INO-5401 in combination with PD-(L)1 in head and neck, bladder cancer, and glioblastoma as validating for the Aspire platform. He continue to like the stock's set-up and remain buyers of the shares.
06/29/18
PIPR
06/29/18
INITIATION
Target $12
PIPR
Overweight
Inovio assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Inovio Pharmaceuticals with an Overweight rating and $12 price target. The stock is "poised for upside" as investors are assigning little value to key programs like VGX-3100, in Phase 3 for the treatment of cervical dysplasia, and INO-5410, in Phase 1/2 for bladder cancer, Raymond tells investors in a research note. He views Inovio's immunotherapy platform as differentiated with a number of key proof of concept data points in coming quarters. The analyst would be a buyer of the stock to levels approaching $12.
10/02/18
STFL
10/02/18
INITIATION
Target $8
STFL
Buy
Inovio resumed with a Buy at Stifel
Stifel analyst Stephen Willey resumed coverage of Inovio with a Buy rating and $8 price target, citing his favorable view of the clinical risk underlying the ongoing Phase 3 VGX-3100 development program in patients with HPV+ cervical HSIL. He sees the company's earlier-stage immuno-oncology development efforts and externally-funded infectious diseases programs as additional sources of longer-term upside, Willey added.
06/29/18
06/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Construction Partners (ROAD) initiated with an Outperform at Imperial Capital. 2. Inovio (INO) assumed with an Overweight at Piper Jaffray. 3. GATX (GATX) initiated with a Buy at Mizuho. 4. Schneider National (SNDR) initiated with a Hold at Stifel. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RHHBY Roche
$0.00

(0.00%)

09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca
$39.55

0.05 (0.13%)

09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
REGN Regeneron
$403.35

9.33 (2.37%)

10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.
10/01/18
CANT
10/01/18
INITIATION
Target $415
CANT
Neutral
Regeneron initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Regeneron Pharmaceuticals with a Neutral rating and $415 price target.
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
10/01/18
LEER
10/01/18
NO CHANGE
Target $512
LEER
Outperform
Regeneron price target raised to $512 from $506 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $512 from $506 after the FDA approved the jointly developed and commercialized REGN/SNY PD-1 antibody cemiplimab, now known as Libtayo. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$81.15

-0.83 (-1.01%)

20:43
10/22/18
10/22
20:43
10/22/18
20:43
Initiation
Exxon Mobil initiated  »

Exxon Mobil assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$54.96

0.07 (0.13%)

, MCD

McDonald's

$166.53

-0.92 (-0.55%)

20:25
10/22/18
10/22
20:25
10/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VZ

Verizon

$54.96

0.07 (0.13%)

MCD

McDonald's

$166.53

-0.92 (-0.55%)

MM

Millennial Media

$0.00

(0.00%)

UTX

United Technologies

$126.42

-2.22 (-1.73%)

LMT

Lockheed Martin

$326.45

-1.77 (-0.54%)

NEE

NextEra Energy

$172.71

-0.76 (-0.44%)

CAT

Caterpillar

$128.64

-2.73 (-2.08%)

BIIB

Biogen

$315.67

-4.18 (-1.31%)

CNC

Centene

$141.34

-1.565 (-1.10%)

GLW

Corning

$30.83

0.06 (0.19%)

PCAR

Paccar

$60.51

0.25 (0.41%)

RF

Regions Financial

$16.39

-0.5 (-2.96%)

FITB

Fifth Third

$25.38

-0.95 (-3.61%)

HBAN

Huntington Bancshares

$13.66

-0.54 (-3.80%)

TRU

TransUnion

$68.59

0.39 (0.57%)

XRX

Xerox

$26.39

-0.47 (-1.75%)

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

JBLU

JetBlue

$16.57

0.04 (0.24%)

GPK

Graphic Packaging

$12.31

-0.4 (-3.15%)

SLCA

U.S. Silica

$15.65

-0.41 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

  • 13

    Dec

  • 14

    Dec

TOT

Total

$59.85

-0.95 (-1.56%)

20:22
10/22/18
10/22
20:22
10/22/18
20:22
Initiation
Total initiated  »

Total assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$64.88

-0.66 (-1.01%)

20:17
10/22/18
10/22
20:17
10/22/18
20:17
Initiation
Royal Dutch Shell initiated  »

Royal Dutch Shell assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$26.39

-0.6 (-2.22%)

20:13
10/22/18
10/22
20:13
10/22/18
20:13
Initiation
Equinor initiated  »

Equinor assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.23

-0.82 (-0.69%)

20:11
10/22/18
10/22
20:11
10/22/18
20:11
Initiation
Chevron initiated  »

Chevron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

COP

ConocoPhillips

$72.06

-0.43 (-0.59%)

20:06
10/22/18
10/22
20:06
10/22/18
20:06
Initiation
ConocoPhillips initiated  »

ConocoPhillips assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BP

BP

$43.15

-0.84 (-1.91%)

20:02
10/22/18
10/22
20:02
10/22/18
20:02
Initiation
BP initiated  »

BP assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:51
10/22/18
10/22
19:51
10/22/18
19:51
Upgrade
Washington REIT, Apple, Amazon.com rating change  »

Washington REIT upgraded…

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:47
10/22/18
10/22
19:47
10/22/18
19:47
Upgrade
JBG Smith Properties, Apple, Amazon.com rating change  »

JBG Smith Properties…

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:38
10/22/18
10/22
19:38
10/22/18
19:38
Periodicals
Arconic Board evaluating $11B Apollo Global offer, Reuters reports »

Arconic is said to have…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

BX

Blackstone

$34.38

-0.28 (-0.81%)

CG

Carlyle Group

$20.46

0.29 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:34
10/22/18
10/22
19:34
10/22/18
19:34
Periodicals
Breaking Periodicals news story on Arconic, Apollo Global »

Arconic to consider $11B…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ENLK

EnLink Midstream Partners

$18.10

-0.19 (-1.04%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Upgrade
EnLink Midstream Partners rating change at Credit Suisse »

EnLink Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Hot Stocks
Helix Energy reports Q3 adjusted EBITDA $58.6M vs. $30.5M last year »

CEO Owen Kratz says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:24
10/22/18
10/22
19:24
10/22/18
19:24
Earnings
Helix Energy reports Q3 adjusted EPS 18c, consensus 11c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

UAL

United Continental

$88.62

1.19 (1.36%)

19:13
10/22/18
10/22
19:13
10/22/18
19:13
Periodicals
United CEO upbeat in memo to workers on Q3, SVBJ reports »

In an internal memo to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$34.98

0.385 (1.11%)

, EUTLF

Eutelsat Communications

$0.00

(0.00%)

19:11
10/22/18
10/22
19:11
10/22/18
19:11
Hot Stocks
Intelsat, SES, Eutelsat in transition on planning to support 5G deployment »

The C-Band Alliance,…

I

Intelsat

$34.98

0.385 (1.11%)

EUTLF

Eutelsat Communications

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CDNS

Cadence Design

$40.62

0.49 (1.22%)

, SSNC

SS&C

$49.91

-0.37 (-0.74%)

19:05
10/22/18
10/22
19:05
10/22/18
19:05
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CDNS

Cadence Design

$40.62

0.49 (1.22%)

SSNC

SS&C

$49.91

-0.37 (-0.74%)

FRBA

First Bank

$12.42

0.015 (0.12%)

ZION

Zions Bancorp

$45.33

-1.64 (-3.49%)

RNST

Renasant

$35.44

-1.1 (-3.01%)

CR

Crane

$87.33

-0.28 (-0.32%)

BRO

Brown & Brown

$29.12

0.27 (0.94%)

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

RH

RH

$109.10

-13.485 (-11.00%)

MC

Moelis

$50.66

-0.21 (-0.41%)

AMTD

TD Ameritrade

$49.89

-0.6 (-1.19%)

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

PTI

Proteostasis

$7.17

-0.77 (-9.70%)

EIGR

Eiger BioPharmaceuticals

$10.65

-1.2 (-10.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 31

    Oct

  • 02

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Mar

  • 23

    Oct

  • 24

    Oct

DIS

Disney

$118.22

-0.59 (-0.50%)

18:55
10/22/18
10/22
18:55
10/22/18
18:55
Periodicals
Disney spends $20M to support Florida's Amendment 3, Bloomberg says »

Disney and the Seminole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

HSBC

HSBC

$40.36

-0.095 (-0.23%)

18:50
10/22/18
10/22
18:50
10/22/18
18:50
Periodicals
HSBC teams up with Avant to offer personal loans, Bloomberg says »

HSBC Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSFS

WSFS Financial

$43.08

-0.46 (-1.06%)

18:49
10/22/18
10/22
18:49
10/22/18
18:49
Earnings
WSFS Financial reports Q3 EPS 96c, consensus 92c »

Reports Q3 NII $63.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IQV

Iqvia

$126.36

-0.52 (-0.41%)

, CRM

Salesforce

$142.92

2.47 (1.76%)

18:22
10/22/18
10/22
18:22
10/22/18
18:22
Recommendations
Iqvia, Salesforce analyst commentary at Piper Jaffray »

Iqvia price target raised…

IQV

Iqvia

$126.36

-0.52 (-0.41%)

CRM

Salesforce

$142.92

2.47 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

  • 03

    Mar

BK

BNY Mellon

$46.47

-0.94 (-1.98%)

18:20
10/22/18
10/22
18:20
10/22/18
18:20
Hot Stocks
BNY Mellon, Bank of the West reach pact on new real-time payments solution »

BNY Mellon and Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLGX

CoreLogic

$45.36

-0.01 (-0.02%)

18:07
10/22/18
10/22
18:07
10/22/18
18:07
Hot Stocks
CoreLogic to acquire Symbility Solutions for CAD159.5M »

Symbility Solutions and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ABBV

AbbVie

$84.27

-3.74 (-4.25%)

18:04
10/22/18
10/22
18:04
10/22/18
18:04
Hot Stocks
AbbVie reports 'positive' data from Phase 2b/3 study of upadacitinib »

AbbVie announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.